Roche Products
| Brand Name | Generic Name | |
| Actemra | Tocilizumab | |
| Avastin | Bevacizumab | |
| Cellcept | Mycophenolate mofetil | |
| Herceptin | Trastuzumab | |
| Herceptin SC | Trastuzumab (subcutaneous) | |
| Mircera | Methoxy polyethylene glycol-epoetin beta | |
| Recormon | Epoetin beta | |
| Ristova | Rituximab | |
| Ropegra | Peginerferon alfa-2a (40KD) | |
| Tarceva | Erlotinib | |
| Valcyte | Valganciclovir | |
| Xeloda | Capecitabine | |
| TAMIFLU | Oseltamivir phosphate | |
| Kadcyla | Ado-trastuzumab emtansine | |
| Gazyva | Obinutuzumab | |
| Perjeta | Pertuzumab | |
| Tecentriq▼ |
Atezolizumab | |
| Actemra | Tocilizumab | |
| Ocrevus▼ |
Ocrelizumab | |
| Mabthera SC | Rituximab (subcutaneous) |
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Health care professionals are asked to report any suspected adverse reactions at [email protected]